14 completed, 6 recruiting, 5 active not recruiting, 3 terminated. 12 Phase 2, 6 Phase 1, 5 Phase 3, 2 Phase 4, 1 Early Phase 1.
Follow Giant Cell Tumor of Tendon Sheath: new trials by email Literature Review of Giant Cell Tumor of Tendon Sheath trials Research Report on Giant Cell Tumor of Tendon Sheath
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor Pimicotinib, Tumor resection surgery - Tenosynovial Giant Cell Tumor, Diffuse | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 84 | 2027-10-01 | 2026-07-16 |
| A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT DCC-3014 - Tenosynovial Giant Cell Tumor | Phase 2 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 18 | 2026-10-31 | 2026-09-22 |
| Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular Synovitis synovial biopsy - Synovitis Villonodular | Not applicable | Recruiting | Nantes University Hospital | 30 | 2026-09-01 | 2026-09-14 |
| Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) Pimicotinib - Tenosynovial Giant Cell Tumor | Phase 2 | Recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 20 | 2026-03-26 | 2026-10-23 |
| Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery Indocyanine Green - Tenosynovial Giant Cell Tumor | Phase 4 | Recruiting | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | 40 | 2026-01-02 | 2026-01-05 |
| MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib Tenosynovial Giant Cell Tumor | Recruiting | Deciphera Pharmaceuticals, LLC | 100 | 2025-09-03 | 2026-07-27 | |
| Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) Emactuzumab, Placebo - TGCT | Phase 3 | Active not recruiting | SynOx Therapeutics Limited | 128 | 2024-10-09 | 2026-07-29 |
| Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) Pimicotinib(ABSK021), Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Abbisko Therapeutics Co, Ltd | 94 | 2023-04-27 | 2026-05-04 |
| A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT AMB-05X - Pigmented Villonodular Synovitis, TGCT | Phase 2 | Completed | AmMax Bio, Inc. | 20 | 2023-01-26 | 2024-07-05 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor Vimseltinib, Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 123 | 2021-10-14 | 2026-03-20 |
| A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 2 | Terminated | AmMax Bio, Inc. | 4 | 2021-09-16 | 2024-05-24 |
| An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS) | Phase 2 | Completed | AmMax Bio, Inc. | 11 | 2021-05-25 | 2024-06-27 |
| A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 2 | Completed | Daiichi Sankyo Co., Ltd. | 9 | 2021-03-15 | 2026-06-24 |
| A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment TURALIO™ - Hepatotoxicity, Tenosynovial Giant Cell Tumor | Recruiting | Daiichi Sankyo | 30 | 2021-01-07 | 2025-10-06 | |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 4 | Completed | Daiichi Sankyo | 32 | 2020-10-20 | 2024-12-30 |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 3 | Active not recruiting | Daiichi Sankyo Co., Ltd. | 40 | 2020-09-25 | 2026-06-26 |
| Screening of Specific Genes for Pigmented Villous Nodular Synovitis Arthroscopic synovectomy - Pigmented Villonodular Synovitis | Completed | Peking University Third Hospital | 60 | 2020-08-03 | 2021-07-08 | |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor ABSK021 - Neoplasms, Tenosynovial Giant Cell Tumor | Phase 1 | Recruiting | Abbisko Therapeutics Co, Ltd | 276 | 2020-01-20 | 2026-03-19 |
| Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants Pexidartinib - Moderate Hepatic Impairment | Early Phase 1 | Completed | Daiichi Sankyo | 16 | 2020-01-07 | 2021-06-22 |
| Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) Tolbutamide, Midazolam, Pexidartinib - Drug Interaction Potential | Phase 1 | Completed | Daiichi Sankyo | 32 | 2018-02-26 | 2021-05-14 |
Showing 20 of 30. Sign in to see all of them.
Synovitis, Pigmented Villonodular (20) · Neoplasms (2) · Synovitis (2) · Arthritis, Rheumatoid (1) · Giant Cell Tumors (1) · Gout (1) · Joint Diseases (1)
Muscular Diseases (30) · Musculoskeletal Diseases (30) · Neoplasms by Histologic Type (30) · Neoplasms, Connective Tissue (30) · Neoplasms, Connective and Soft Tissue (30) · Tendinopathy (30) · Giant Cell Tumors (29) · Joint Diseases (29) · Neoplasms (28) · Synovitis (28) · Arthritis (1) · Autoimmune Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1)
pexidartinib (7) · nilotinib (2) · Bro protein, Drosophila (1) · Indocyanine Green (1) · Midazolam (1) · Tolbutamide (1) · cabiralizumab (1) · emactuzumab (1)
Daiichi Sankyo (6) · AmMax Bio, Inc. (3) · Deciphera Pharmaceuticals, LLC (3) · Abbisko Therapeutics Co, Ltd (2) · Daiichi Sankyo Co., Ltd. (2) · Peking University Third Hospital (2) · Plexxikon (2) · Andrew J. Wagner, MD, PhD (1) · Centre Leon Berard (1) · Five Prime Therapeutics, Inc. (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Nantes University Hospital (1) · Novartis Pharmaceuticals (1) · Ono Pharmaceutical Co., Ltd. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
United States (19) · Netherlands (12) · France (8) · Italy (8) · Poland (8) · China (7) · Spain (7) · United Kingdom (7) · Australia (5) · Canada (5) · Taiwan (4) · Germany (3) · Hungary (3) · Japan (3) · Switzerland (3)
Dorothy Nguyen, MD (3) · Andrew J. Wagner, MD, PhD (1) · Jean Y Blay, Prof, MD (1) · Jean Yves Blay, PR (1) · Maitreyi Sharma, MD (1) · Project Leader (1) · Siqing Fu, MD (1)
PMID 33289960, PMID 21613624, PMID 27041409, PMID 28057477, PMID 29290809, PMID 29571946, PMID 31188797, PMID 31229240, PMID 32224746, PMID 32755241, PMID 33926503, PMID 35230489, PMID 35247274, PMID 35837703, PMID 35932628, PMID 36001000, PMID 36502615, PMID 36869793, PMID 37121591, PMID 37178368, PMID 37593881, PMID 38843860, PMID 39287124, PMID 40841499, PMID 41796601, PMID 42132251, PMID 42473802, PMID 42872549
2014 (1)